The purpose of this study is to establish a safe dose of study cells to give to patients with relapsed/ refractory ALL expressing CD19.
Your blood will be collected to begin the manufacturing process to make the modified immune cells that will be the study treatment. The modified cells will hopefully be more effective at killing your cancer cells than your body's normal cells. The study team will do blood tests and other procedures to confirm it is safe for you to get the modified study cells. If it is safe, you will complete 3 days of pre-treatment chemotherapy, which will prepare your body to accept the study cells better. You will then receive the study cell infusion. Patients enrolled later in the study whose disease does not completely respond may be eligible to receive a 2nd round of chemotherapy and cell infusion. You will need to stay near the hospital after infusion and will be seen frequently in clinic for follow-up visits that may include lab tests, imaging, or biopsies of your tumor. You will continue follow up visits based on how well you have responded to the study treatment
Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Natalie Grover
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Leukemia)
16-1057